The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Campaigns & Insights
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / November / A New Lens on nAMD
Health Economics and Policy Retina News

A New Lens on nAMD

Six-year study suggests phenotype-based classification of nAMD may reveal vision risks missed by conventional subtyping

11/5/2026 2 min read

Share

  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll
Objective:

To compare conventional nAMD subtypes with a classification based on drusen and pachychoroid features for predicting long-term visual and atrophic outcomes.

Approach:
  • Study design: Retrospective cohort study of 120 treatment-naïve eyes followed for at least six years at a single center in Japan.
  • Treatment and classification: All eyes received three anti-VEGF loading doses followed by pro re nata treatment. Researchers classified eyes using conventional categories and a newer system: drusen, pachychoroid, mixed, and other.
  • Outcomes: The study assessed maintenance of best-corrected visual acuity (BCVA) and the prevalence of retinal pigment epithelial and outer retinal atrophy (RORA) and complete RORA (cRORA).
Key Findings:
  • Overall, 71% of eyes maintained BCVA, defined as losing fewer than 15 ETDRS letters.
  • Visual retention did not differ significantly among typical nAMD, PCV, and RAP under conventional classification.
  • With the newer classification, 82% of pachychoroid-type eyes maintained vision, compared with 38% of drusen-type eyes.
  • BCVA worsened when RORA or cRORA emerged: mean logMAR changed from 0.10 to 0.35 at RORA onset and from 0.36 to 0.82 at cRORA onset.
  • At six years, cRORA prevalence was 61.5% in the drusen group and 27.2% in the pachychoroid group; final cRORA prevalence differed significantly across the newer phenotypes.
  • Conventional subtypes showed no significant differences in RORA or cRORA prevalence.
Interpretation:

The study authors suggest that classification by drusen and pachychoroid features may distinguish long-term risks of vision loss and atrophy more clearly than conventional nAMD categories. They propose that differences in underlying disease biology may contribute to the observed contrast.

Limitations:
  • The study was retrospective and conducted at a single Japanese center.
  • Some subgroups, particularly RAP, were small.
  • Different anti-VEGF agents were used during the study period.
  • The authors state that prospective studies are needed to establish causality.
Conclusion:

The findings suggest that drusen- and pachychoroid-based phenotyping may provide prognostic information about long-term atrophy and vision outcomes; the authors call for prospective studies.

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: